

A grayscale photograph of a person's hand holding a white, handheld diagnostic device. The device has a small screen and two buttons. In the background, a tablet is held by another hand, displaying a video call with a female doctor in a white lab coat. The overall scene suggests a telemedicine or remote diagnostic application.

ATOMO DIAGNOSTICS

Q3 RESULTS & INVESTOR PRESENTATION

28 APRIL 2026

INTRODUCTION

Investor Overview • APRIL 2026

Atomo is an innovative diagnostics company with unique products in the point-of-care (POC) test market

ASX: AT1

ATOMO'S STRATEGIC FOCUS?

Point of Care Diagnostics Tests – Building a high value portfolio:

- **HIV** – Commercially launched: recognised market leader in ANZ and UK
- **Active Syphilis** – unique test that can distinguish active & prior treated Syphilis in a POC format (In-Development)
- **Liver Function** – an easy-to-use test to diagnose liver damage common with several chronic diseases (In Development)

Partner Supply – Critical Supply of Pascal Proprietary Cassettes:

- Supply to Lumos Diagnostics for their FDA CLIA waived FebriDx® test
- Supply to NG Biotech for their European IVDR approved Blood pregnancy
- Building a customer base that increasingly recognises the value of reliability, with two new customers recently secured

WHO IS ATOMO?


- **We develop, manufacture & supply** innovative rapid diagnostic tests, including Self-tests to international markets
- **Significant growth opportunity** as Atomo expands its rapid test portfolio and demand for its proprietary test cassettes grows
- **We are a trusted critical supply partner to diagnostic companies** utilising our unique device usability to secure high value product registrations and access large markets
- **Best-in-class usability, acceptability and performance** — increasingly recognised as delivering unmatched simplicity and reliability in point-of-care testing

Q3 ACTIVITY HIGHLIGHTS

Investor Overview • APRIL 2026

ASX: AT1

- **Lumos' FebriDx® receives CLIA waiver approval from the US FDA**
 - *unlocks material growth in the US market for Pascal supply for FebriDx®*
 - *provides predicate pathway to US market for Atomo's diagnostic test products*
 - *validates a material market expansion opportunity for new customers on Pascal*
- **Sales orders worth more than \$2 million received during the quarter**



APPENDIX 4C OVERVIEW

Investor Overview • APRIL 2026

ASX: AT1

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B

Rule 4.7B

Name of Entity

Atomo Diagnostics Limited

ABN

37 142 925 684

Quarter Ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current Quarter A\$'000	Year to date (9 months) A\$'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,572	3,553
1.2 Payments for		
(a) research and development	(445)	(568)
(b) product manufacturing and operating costs	(1,088)	(3,134)
(c) advertising and marketing	(25)	(126)
(d) leased assets	-	-
(e) staff costs	(667)	(1,991)
(f) administration and corporate costs	(321)	(909)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	17	51
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	165	1,370
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(792)	(1,755)

Consolidated statement of cash flows	Current Quarter A\$'000	Year to date (9 months) A\$'000
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	3,512	3,220
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(792)	(1,755)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	5	(41)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(29)	1,162
4.5 Effect of movement in exchange rates on cash held	(90)	18
4.6 Cash and cash equivalents at end of period	2,605	2,605

8. Estimated cash available for future operating activities	A\$'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(792)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	2,605
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	2,605
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	3.30


In accordance with ASX Listing Rule 4.7C.3, Atomo advises that an amount of \$148k was paid during the quarter covering Atomo's Managing Director salary and Non-Executive Directors fees.

Q3 FINANCIAL HIGHLIGHTS

Investor Overview • APRIL 2026


ASX: AT1

CASH FLOW ACTIVITIES




- Cash on hand as at Q3 FY26 finished on \$2.6m and debt-free
- Cash receipts for the quarter totaled \$1.8m made up of \$1.6m customer receipts and \$165k from the on-going Syphilis CRC-P development grant
- Cash outflows totaled \$2.6m for the quarter, reflecting continued investment in program delivery, product supply and efforts progressing new programs and development opportunities

REVENUE & OPERATING EXPENSES



- **Revenue of \$814k**, bringing YTD revenue to ~\$3m (up 4% comparable YTD period)
- OEM ~\$495k: increased orders for Pascal from FebriDx
- HIV ~\$270k sales
- Additional orders received during the period >\$2 million

- Overall, for the quarter expenses totaled \$1.8m
- Operating expenses continues to be managed and deployed towards strategic growth opportunities
- This does not take into account other income from CRC-P grant and government R&D rebates, further improving bottom line by ~15-20%



INVESTOR PRESENTATION



Innovating novel and disruptive lateral flow solutions in point-of-care and self-test

ATOMO

Innovating novel and disruptive lateral flow solutions in point of care and self-testing

Direct participation in multiple growing, high-volume diagnostic markets with Atomo's finished tests that offer excellent ease-of-use & performance – **HIV, Syphilis, Liver Function and others**

Pascal enabled FDA CLIA waiver of Lumos' FebriDx® provides step-change for Atomo, by;

- unlocking significant growth in the US market for Pascal supply for FebriDx®
- providing a predicate pathway to US market for Atomo's diagnostic test products
- validating a valuable market expansion opportunity via Pascal for new customers

Global commercial market footprint established – sales channels into Australian, US, European, Asian and African markets

Innovative patented proprietary technology that is proven to deliver a level of user reliability, performance and acceptability unmatched in decentralised settings



FINANCIAL SUMMARY

Investment Highlights • APRIL 2026

ASX: AT1

- ✓ Atomo is seeing strong momentum in its established revenue channels including HIV Tests and Pascal Cassettes
- ✓ Expansion of customer base across new products pipeline and new partners for Atomo cassettes

FY25
REVENUE
A\$3.8M



**STRONG GROWTH
TARGETED FY26**




- ✓ **Clean debt free balance sheet**
- ✓ Atomo validating a second-generation blister machine and high-cavity mould tooling to support expansion of capacity and improve economies of scale



- ✓ Capital focus on new test portfolio development / commercialisation – Syphilis, Liver etc/
- ✓ Non-dilutive funding grants (Syphilis) and selective licensing of proven assets (Liver) used to support low-cost development and go to market

- ✓ EBITDA trending towards breakeven as existing revenue channels grow and product offerings expand



EXTENSIVE IP & PRODUCT REGISTRATIONS

IP & Registrations • APRIL 2026

ASX: AT1

7 patent families and extensive proprietary know-how across 30+ countries — underpinning a defensible competitive position

PATENT FAMILIES

Family 1

Diagnostic System

PCT/AU2011/000315

Family 2

Sampling Assembly

PCT/AU2011/001321

Family 3

Fluid Control Integrated Testing Devices

PCT/IB2014/066210

Family 4

Integrated Fluid Module

PCT/AU2016/051134

Family 5

Integrated Blood Testing Device

PCT/AU2018/051114

Family 6

Pre-Mix Test Vessel

PCT/AU2022/050812

Family 7

Automated Verification & Guidance

PCT/AU2022/051076

PRODUCT REGISTRATIONS

Atomo HIV Self-Test


- TGA — Australia
- WHO PQ — LMIC
- CE Mark — UK & Europe

Pascal enabled Pregnancy Test

- CE Mark — UK & Europe
- ANVISA — Brazil

Pascal enabled FebrIDx®

- FDA 510k & CLIA Waiver — US
- CE Mark — UK & Europe
- TGA — Australia



EXPANDING TEST PORTFOLIO

Building a portfolio of innovative point-of-care rapid diagnostic tests for global markets

PRODUCT	INDICATION	DEVELOPMENT	VALIDATION & REGULATORY APPROVAL	LAUNCH
HIV	HIV Detection (Self-Testing)			• LAUNCHED – ANZ, UK & LMIC
	HIV Detection (Professional Use)		• APPROVED – OPPORTUNITY FOR GEN IV UPGRADE	
Pregnancy	Pregnancy Detection (Self & Professional)			• LAUNCHING – Europe. ATOMO MARKETS TO FOLLOW
Syphilis	Distinguish active vs prior treated infection		► DEVELOPMENT COMPLETE – CLINICAL TRIALS COMMENCING 2026	
Liver / ALT	Liver disease screening & monitoring		► TEST DEVELOPMENT COMPLETE – CLINICAL GO TO MARKET DEVELOPMENT COMMENCED	

TESTS UNDER CONSIDERATION	PSA Prostate cancer screening	Stroke Acute neurological triage	Coeliac Gluten sensitivity detection	HIV Gen 4 4th generation HIV detection	Others TBD Subject to commercial assessment
---------------------------	---	--	--	--	---

HIV SELF-TEST — MARKET OPPORTUNITY

ASX: AT1

HIV Momentum • APRIL 2026

Consistent order flow from established channels supports sustained growth in HIV revenues

A\$200M SOM*

* Global excl. US

HIV Self-Test Serviceable Obtainable Market Estimate

10% CAGR

Self-Test Market growth rate



EUROPE & REST OF WORLD EXPANSION AND SUSTAINABILITY

250,000+ Tests

Estimated at-home testing market in UK via public health

8 European Countries

Active pipeline via Newfoundland Diagnostics

~500k Tests

Ordered via the Global Fund during FY26

Europe

- Established in BOOTS and Tesco in UK
- Pharmacy/retail and public health demand
- Expansion across Western & Northern Europe

APAC

- Active discussions with national distributors
- Leverage TGA and WHO Prequalification
- Prioritising commercially viable markets

Global Health

- Selective market access via Viatris partnership
- Integration into donor-funded & public programmes
- High-volume scale contingent on funding support

Scalable Commercial Model

Proven ANZ market creation strategy applied globally — prioritising funded markets, established procurement systems, and higher-margin regions with registration.

* SOM = Serviceable Obtainable Market, value estimated by Atomo based on 2025 data

HIV SELF-TEST – ANZ BUSINESS

Transitioning from Proven Revenue to Scalable Global Expansion

ASX: AT1

A\$8M SOM*

ANZ HIV Self-Test – Serviceable Obtainable Market Estimate

> 85%

Australian HIV Self-Test Market Share

TWO KEY GROWTH DRIVERS

Retail Market Growth

Atomo has created the pharmacy HIV self-testing model in ANZ and is now scaling it nationally through expanded ranging across all national chains, increased shelf presence, and repeat testing behaviors

Public Health Procurement

Established pilot programs now adopted through public health procurement providing a strong volume foundation, with Atomo positioned to scale into expanding national programs as governments accelerate self-test adoption



NSW Health
Vending Machine

Current Position

- First to scale a national pharmacy-based HIV self-testing model
- Leading HIV self-test provider in ANZ pharmacy retail
- Additional access: Online channels & Chemist Warehouse NZ

12-Month Growth Plan

- **Pharmacy Expansion** — 600+ new rollout opportunity
- **Channel Expansion** — Adult retail, specialty channels, online marketplace, NZ growth
- **Public Health Scale-Up** — Potential Government & NGO programs and recurring volume

Atomo has successfully created and leads the HIV self-testing market in ANZ, with a clear and executable pathway to scale further through pharmacy expansion, channel diversification, and increased public health procurement

* SOM = Serviceable Obtainable Market, value estimated by Atomo based on 2025 data

ACTIVE SYPHILIS – HIGH-LEVERAGE EXPANSION

ASX: AT1

Active Syphilis • APRIL 2026

Addressing significant unmet clinical and market needs

- *no existing rapid test can reliably distinguish active & prior infection*
- *no current test format is optimised for easy, reliable self-testing*

1.6M

UK Syphilis Tests in 2024 *

**Established demand
existing HIV Channels**

Atomo plans to leverage existing HIV commercial infrastructure, partnerships and sales channels to enable rapid, capital-efficient market entry

- **Channel Leverage** — Similar users, procurement bodies, and distribution channels as HIV testing
- **Immediate Commercialisation** — Deployable alongside existing HIV test programs
- **Efficiency** — Lower cost of entry, faster time to launch and scale revenue



Market Drivers

- Funded public health programmes
- Community & decentralised testing
- Increasing adoption of self-testing



Development & Readiness

Verification Complete

Strong product development and verification data

Clinical Trials Commencing

Progressing toward commercialisation

Regulatory Engagement

Positive engagement with regulators and stakeholders

Dual Pathway

Professional use and self-testing channels ready

- <https://www.gov.uk/government/publications/tracking-the-syphilis-epidemic-in-england/tracking-the-syphilis-epidemic-in-england-2015-to-2024>

UNIQUE LIVER TEST – BROAD OPPORTUNITY

ASX: AT1

Liver Test • APRIL 2026

- *Multiple large addressable markets across chronic disease management, drug safety and at-risk population screening*
- *Global license secured from Burnet Institute with development substantially complete and good performance established*

01

Drug-Induced Liver Injury (DILI)

Monitoring for common drug types requiring ALT surveillance — TB drugs, Methotrexate, Leflunomide, Azathioprine, Valproate, Amiodarone, long-term Diclofenac.

Evaluation underway in US trial by multinational pharmaceutical company

Drug-Induced Liver Injury (DILI)



2025 SOM - A\$72M
2032 SOM - A\$100M

02

Hepatitis B & C Management

Diagnosis and treatment management — evaluation trial planned to assess use in determining commencement of Hepatitis B drug treatment based on ALT level.



2025 SOM - A\$53M
2032 SOM - A\$86M

03

Fatty Liver Disease Screening

High correlation between elevated ALT and fatty liver disease — affecting 1.5B+ people globally. Significant opportunity for home screening and monitoring of at-risk and diagnosed patients.

Fatty Liver Disease



2032 SOM - A\$80M

04

Alcoholic Liver Disease Screening

Elevated ALT is a key early indicator of alcohol-related liver cell injury and inflammation — enabling immediate home screening across the 300 million people affected globally.



Alcoholic Liver Disease

2032 SOM - A\$25M

* SOM = Serviceable Obtainable Market, value estimated by Atoo based on 2025 data

PARTNERING BUSINESS — FY26 HIGHLIGHTS

ASX: AT1

Pascal OEM • APRIL 2026

Transformational growth anticipated with Pascal revenues; CLIA waiver of Lumos' test in the US drives step-change in demand and increases visibility in market


US\$313m

Lumos anticipated FebriDx revenue over contract term

> 99%

Concordance between trained and untrained users of Pascal FebriDx in US CLIA waiver study

- **Lumos' FebriDx® secures US FDA CLIA waiver approval** - CLIA waiver expands the US addressable by around 15 times to over US\$1 billion*
- **Each FebriDx test sold generates a Pascal cassette order** — Atomo receives a portion of the transfer price, creating a direct and scalable revenue link to FebriDx sales
- **Lumos six-year agreement with PHASE Scientific** — FebriDx product revenues of up to US\$313m anticipated over the term based on CLIA waiver & contracted MOQs
- **~1,600% increase in Pascal FebriDx orders** in H1 FY26 vs H1 FY25 — reflecting commercial adoption of the Pascal platform following US clinical validation
- **Growing pipeline of Pascal customers** across high value diagnostic applications — additional international customers (UK and Canada) recently secured



* Doug Ward – CEO, Lumos Diagnostics
<https://www.proactiveinvestors.com/companies/news/1076809/lumos-diagnostics-submits-clia-waiver-application-for-febridx-1076809.html>

EXPANDING OPERATIONAL CAPABILITIES


ASX: AT1

Operations • APRIL 2026

Scaling infrastructure to support growing demand for Atomo Tests and Test Cassettes

NORTH AMERICA

- Outsourced US operations for blister production in PA
- **Pascal Supplied to Lumos in California**



EUROPE

- Atomo HIV ST supplied to Newfoundland in UK and now Europe
- **Pascal Supplied to NG Biotech in France**



SOUTH AFRICA

- Atomo South Africa facility – assembly of HIV Tests (Syphilis planned)



CHINA

- Outsourced cassette moulding / assembly



AUSTRALIA

- Headquarters:
- Innovation Centre & Blister Manufacturing
- Direct to market HIV distribution with established brand recognition



Innovating novel and disruptive lateral flow solutions in point-of-care and self-test

ATOMO

Innovating novel and disruptive lateral flow solutions in point of care and self-testing

Direct participation in multiple growing, high-volume diagnostic markets with Atomo's finished tests that offer excellent ease-of-use & performance – **HIV, Syphilis, Liver Function and others**

Pascal enabled FDA CLIA waiver of Lumos' FebriDx® provides step-change for Atomo, by;

- unlocking significant growth in the US market for Pascal supply for FebriDx®
- providing a predicate pathway to US market for Atomo's diagnostic test products
- validating a valuable market expansion opportunity via Pascal for new customers

Global commercial market footprint established – sales channels into Australian, US, European, Asian and African markets

Innovative patented proprietary technology that is proven to deliver a level of user reliability, performance and acceptability unmatched in decentralised settings



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of Entity

Atomo Diagnostics Limited

ABN

37 142 925 684

Quarter Ended ("current quarter")

31 March 2026

Consolidated statement of cash flows		Current Quarter A\$'000	Year to date (9 months) A\$'000
1. Cash flows from operating activities			
1.1 Receipts from customers		1,572	3,553
1.2 Payments for			
(a) research and development		(445)	(568)
(b) product manufacturing and operating costs		(1,088)	(3,134)
(c) advertising and marketing		(25)	(126)
(d) leased assets		-	-
(e) staff costs		(667)	(1,991)
(f) administration and corporate costs		(321)	(909)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		17	51
1.5 Interest and other costs of finance paid		-	-
1.6 Income taxes paid		-	-
1.7 Government grants and tax incentives		165	1,370
1.8 Other (provide details if material)			
1.9 Net cash from / (used in) operating activities		(792)	(1,755)
2. Cash flows from investing activities			
2.1 Payments to acquire or for:			
(a) entities		-	-
(b) businesses		-	-
(c) property, plant and equipment		5	(41)
(d) investments		-	-
(e) intellectual property		0	0
(f) other non-current assets		-	

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current Quarter A\$'000	Year to date (9 months) A\$'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	5	(41)
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	40	1,404
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(1)	(65)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(68)	(176)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(29)	1,162
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	3,512	3,220
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(792)	(1,755)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	5	(41)

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current Quarter A\$'000	Year to date (9 months) A\$'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(29)	1,162
4.5	Effect of movement in exchange rates on cash held	(90)	18
4.6	Cash and cash equivalents at end of period	2,605	2,605

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current Quarter A\$'000	Previous Quarter A\$'000
5.1	Bank balances	2,605	3,512
5.2	Term deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,605	3,512

6.	Payments to related parties of the entity and their associates	Current Quarter A\$'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	148
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity

	Total facility amount at quarter end A\$'000	Amount drawn at quarter end A\$'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangement	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-

7.5 **Unused financing facilities available at quarter end**

-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	A\$'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(792)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	2,605
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	2,605
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	3.30

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Not applicable.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Not applicable.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Not applicable.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 April 2026

Authorised by:The Board

(Name of body or officer authorising release see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the *[name of board committee – eg Audit and Risk Committee]*". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.